TransMedics Group Inc
Cerrado
SectorSanidad
72.85 -3.8
Resumen
Variación precio
24h
Mínimo
72.7
Máximo
77.36
Ingresos | -98M 7.3M |
|---|---|
Ventas | 13M 174M |
P/B Media del Sector | 17.272 49.712 |
BPA | 0.3 |
Margen de beneficios | 4.206 |
Empleados | 898 |
EBITDA | -4.9M 28M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +57.78% upside |
Próximas Ganancias | 29 jul 2026 |
|---|
Capitalización Mercado | -745M 2.6B |
|---|---|
Apertura anterior | 76.65 |
Cierre anterior | 72.85 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
155 / 342 Clasificación en Healthcare
TransMedics Group Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.